Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 893191 | ISIN: DK0011048619 | Ticker-Symbol: 2P4
Frankfurt
23.10.25 | 08:09
0,156 Euro
-1,27 % -0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOPORTO A/S Chart 1 Jahr
5-Tage-Chart
BIOPORTO A/S 5-Tage-Chart

Aktuelle News zur BIOPORTO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.09.BioPorto A/S: Grant of Warrants1
BIOPORTO Aktie jetzt für 0€ handeln
28.08.BioPorto A/S: ProNephro AKI (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto's collaboration with Roche Diagnostics.5
15.08.BioPorto A/S: BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.126August 15, 2025Announcement no. 19 BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. Copenhagen...
► Artikel lesen
29.07.BioPorto A/S to host an investor webcast on the results for the first half of 20251
28.07.BioPorto A/S: BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.1
27.06.BioPorto A/S: Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US262June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 - BioPorto A/S ("BioPorto"...
► Artikel lesen
12.06.BioPorto A/S: Grant of Warrants1
10.06.BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy435June 10, 2025Announcement no. 16 BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIRE)...
► Artikel lesen
08.05.BioPorto A/S: Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.192May 8, 2025Announcement no. 15Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. Interim results and a business update...
► Artikel lesen
28.04.BioPorto A/S: Grant of Warrants2
28.04.BioPorto A/S to host first quarter 2025 earnings webcast for investors1
25.04.BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes393April 25, 2025Announcement no. 12BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes Completion of share capital increase COPENHAGEN, DENMARK, April 25...
► Artikel lesen
11.04.BioPorto A/S: Resolutions of the Annual General Meeting167April 11, 2025 Announcement no. 9 Resolutions of the Annual General Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 11, 2025, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: BIOPOR)...
► Artikel lesen
20.03.BioPorto A/S: BioPorto announces the Annual Report for 2024201March 20, 2025Announcement no. 06BioPorto announces the Annual Report for 2024 Copenhagen, Denmark, March 20, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or company) (CPH:BIOPOR), an in vitro...
► Artikel lesen
19.03.BioPorto A/S: BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029107March 19, 2025Announcement no. 05BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029 Copenhagen, Denmark, March 19, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or Company)...
► Artikel lesen
29.01.BioPorto A/S appoints new interim Chairman of the Board336January 29, 2025Announcement no. 02 BioPorto A/S appoints new interim Chairman of the Board COPENHAGEN, DENMARK, January 29, 2025, (GLOBE NEWSWIRE) - BioPorto A/S CVR-no. 17500317 (BioPorto...
► Artikel lesen
06.01.BioPorto A/S: Preliminary Financial Figures for the 2024 Fiscal Year148January 6, 2025 Announcement no. 01 Preliminary Financial Figures for the 2024 Fiscal Year COPENHAGEN, DENMARK, January 6, 2025, (GLOBE NEWSWIRE) - BioPorto A/S CVR-no. 17500317 (BioPorto or Company)...
► Artikel lesen
14.11.24BioPorto A/S: BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024194November 14, 2024Announcement no. 22 BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 Revenue growth and strategic execution COPENHAGEN,...
► Artikel lesen
28.10.24BioPorto A/S: BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests27128 October 2024Announcement no. 19 BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests COPENHAGEN, DENMARK and BOSTON, MA, USA, October...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1